AlphAIAlphAI — Financial news for AI agents
aol.comSEP 152 min read$CTNM

Johnson & Johnson Partner Contineum Slides as Depression Drug Fails

Contineum Therapeutics (CTNM) shares fell 9.58% after its Phase 2 MOONLIGHT-1 trial for depression drug JNJ-5120/PIPE-307, developed with Johnson & Johnson (JNJ), missed its primary efficacy endpoint. JNJ is reviewing data to determine next steps. CTNM's stock is near key support at $13.60 and resistance at $15.34.

Original reporting
aol.com
Published Sep 15, 2026, 5:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails — source image
Source · aol.com
Decision brief

The 30-second read

$CTNMBearishMed
01

Why it matters

The trial failure is the primary catalyst for the stock's 9.58% drop, highlighting the risk inherent in biotech clinical stages.

02

Market read

CTNM's share price fell sharply on the news, reflecting immediate market reaction to the negative data.

03

What to watch

Potential for Johnson & Johnson to continue development or seek a partner, which could mitigate downside.

Relevance 7/10Novelty 8/10Timing: premarket today

Background

The article discusses Contineum Therapeutics' recent stock move tied to a failed Phase 2 trial, with brief technical analysis and momentum scores.

Company-level read

Ticker impact

$CTNMBearishHigh confidence
Context

Contineum Therapeutics reported its Phase 2 MOONLIGHT-1 trial missed the primary efficacy endpoint for JNJ-5120/PIPE-307 in major depressive disorder.

Expected impact

downward pressure, potential further decline if no mitigating data emerges

Evidence & confidence

Phase 2 failure is material for a biotech and typically triggers a sell-off.

Market effects

Sector

May weigh on other depression‑drug pipelines and biotech peers awaiting trial data.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minimal global impact beyond biotech investors.

Counterpoint

What could challenge this read

If exploratory endpoints show promise, the stock could rebound on a short‑term bounce.

Key entities

  • company
    Contineum Therapeutics, Inc.

    Biotech firm developing depression drug JNJ-5120/PIPE-307.

Read at source← All news

Also covered by

3 outlets

Related articles

OCT 12
$CTNMHigh

Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results

Contineum Therapeutics (CTNM) shares rose 27% premarket after Bristol Myers Squibb (BMY) reported positive Phase 3 trial results for a pulmonary fibrosis treatment targeting the same pathway as CTNM's lead drug, PIPE-791. BMY's trial met its primary endpoint, showing improved lung function. CTNM's stock was indicated at $16.99, up from $13.38. The results may impact CTNM's valuation, though its drug remains in Phase 2.

finance.yahoo.com2 min
OCT 12
MedAI 8/10

Why is Contineum Therapeutics stock surging today?

Contineum Therapeutics stock surged 21.1% after Bristol Myers Squibb's Phase 3 trial for admilparant in pulmonary fibrosis met its primary endpoint. Contineum's PIPE-791, an LPA1 antagonist, benefits from this validation. Analysts have Buy ratings with targets ranging from $20 to $24. The move is driven by company-specific news, not broader market trends.

investing.com2 min
OCT 12
$CTNMHighAI 8/10

Contineum Therapeutics stock surges on Bristol Myers trial win

Contineum Therapeutics (CTNM) shares rose 27% in pre-market trading after Bristol Myers Squibb's Phase 3 trial for admilparant in idiopathic pulmonary fibrosis met its primary endpoint. Contineum's PIPE-791 targets the same biological pathway. CTNM was indicated at $16.99, up from $13.38. Stifel previously noted the trial's importance for Contineum's valuation.

uk.investing.com1 min
SEP 25
$CTNMMedAI 8/10

J&J and Contineum’s Depression Drug Missed Phase 2 Goal. What Comes Next?

Contineum Therapeutics (CTNM) and Johnson & Johnson (JNJ) reported that their depression drug, JNJ-5120/PIPE-307, failed to meet the primary endpoint in a Phase 2 trial. The drug showed no new safety issues but did not demonstrate the required efficacy in treating major depressive disorder. JNJ is analyzing additional data to determine the next steps for the program.

insidermonkey.com4 min